Skip to main content
PRE
NASDAQ Life Sciences

Prenetics CFO of IM8 Buys $497,700 of Stock in Open Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Diagnostics & Research Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$22.17
Mkt Cap
$398.586M
52W Low
$7.18
52W High
$23.63
52W Position info
209% above low
Off High info
6.2% below high
Rel. Volume info
2.3× avg
Market data snapshot near publication time

PRE has more than doubled off its 52-week low of $7.18 on elevated volume (2.3× avg).

Summary

CFO of IM8 (US) LLC Brian J Rosin bought $497,700 of Prenetics stock in the open market on August 24-25, 2026, at $21.19-$22.80 per share.


Key Events · Ownership and Investor Activity · PRE

  • CFO of IM8 Buys $497,700 in Open Market

    Brian J Rosin, CFO of IM8 (US) LLC, acquired 23,100 Class A ordinary shares for $497,700 in two open-market purchases on August 24-25, 2026, at $21.19-$22.80 per share.

  • Cluster of Insider Accumulation

    This purchase follows CEO Danny Yeung's $502K open-market buy disclosed on August 25, 2026, creating a two-insider accumulation signal within one week.

  • Post-Transaction Holdings

    Rosin now directly holds 23,100 shares, representing his entire reported position in Prenetics.

  • Context: Strong IM8 Momentum

    The purchase comes after IM8 secured a $1 billion non-dilutive financing facility from General Catalyst and raised FY2026 revenue guidance to $220-230M.


Analysis · PRE · Life Sciences

Brian J Rosin, CFO of IM8 (US) LLC, bought 23,100 shares for $497,700 on August 24-25 at $21.19-$22.80 per share. This follows CEO Danny Yeung's $502K open-market purchase disclosed just one day earlier, creating a cluster of insider accumulation at the top of the company. The purchase is real money out of pocket, not an option exercise, and comes amid strong IM8 brand momentum and a $1 billion non-dilutive financing facility.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, PRE was trading at $22.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $398.6M. The 52-week trading range was $7.18 to $23.63. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

PRE - Latest Insights

PRE
Nov 05, 2026, 8:53 AM EST
Filing Type: 6-K
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $16.84 info
Change: +$0.640 (+4%) info
Market Cap: $279.642M info
PRE
Nov 05, 2026, 8:30 AM EST
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $16.20
Real-time Price: $16.84 info
Change: +$0.640 (+4%) info
Market Cap: $279.642M info
PRE
Nov 02, 2026, 9:13 AM EST
Filing Type: 6-K
Importance Score:
7
Price at Filing: $18.23
Real-time Price: $16.84 info
Change: -$1.39 (-8%) info
Market Cap: $279.642M info
PRE
Oct 13, 2026, 6:53 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $21.16
Real-time Price: $16.84 info
Change: -$4.32 (-20%) info
Market Cap: $279.642M info
PRE
Aug 24, 2026, 9:41 PM EDT
Filing Type: 4
Importance Score:
7
Price at Filing: $21.82
Real-time Price: $16.84 info
Change: -$4.98 (-23%) info
Market Cap: $279.642M info